CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
KR20020063282A
(ko)
*
|
1999-12-28 |
2002-08-01 |
아지노모토 가부시키가이샤 |
경구 투여용 당뇨병 치료제
|
US6627611B2
(en)
*
|
2000-02-02 |
2003-09-30 |
Kotobuki Pharmaceutical Co Ltd |
C-glycosides and preparation of thereof as antidiabetic agents
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
BR0115055A
(pt)
*
|
2000-10-30 |
2003-12-30 |
Ortho Mcneil Pharm Inc |
Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
JP2004525109A
(ja)
*
|
2001-02-15 |
2004-08-19 |
キング・ファーマシューティカルズ・インコーポレイティッド |
安定化された甲状腺ホルモン医薬組成物、及びその製法
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
CN100577175C
(zh)
*
|
2001-04-04 |
2010-01-06 |
奥索-麦克尼尔药品公司 |
包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
|
ES2258141T3
(es)
*
|
2001-04-11 |
2006-08-16 |
Bristol-Myers Squibb Company |
Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
|
WO2003011880A1
(fr)
*
|
2001-07-31 |
2003-02-13 |
Kissei Pharmaceutical Co., Ltd. |
Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
US20030175337A1
(en)
*
|
2001-10-29 |
2003-09-18 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
AU2002348276A1
(en)
*
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
WO2003059378A2
(en)
*
|
2001-12-29 |
2003-07-24 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
WO2003075911A1
(en)
*
|
2002-03-11 |
2003-09-18 |
Peter Zahradka |
Use of ppar alpha agonists for the treatment of vascular and renal diseases
|
US20050215489A1
(en)
*
|
2002-03-14 |
2005-09-29 |
Bayer Pharmaceuticals Corporation |
Methods of treating diabetes using pde 11a inhibitors
|
EP1500403A4
(en)
*
|
2002-04-26 |
2008-09-17 |
Ajinomoto Kk |
MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
|
US7956041B2
(en)
|
2002-04-26 |
2011-06-07 |
Ajinomoto Co., Inc. |
Prophylactic and therapeutic agent of diabetes mellitus
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
TWI254635B
(en)
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
AU2003272903A1
(en)
*
|
2002-10-04 |
2004-04-23 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258008B4
(de)
*
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
CA2512389A1
(en)
|
2003-01-03 |
2004-07-29 |
Bristol-Myers Squibb Company |
Methods of producing c-aryl glucoside sglt2 inhibitors
|
EP1457206A1
(en)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Combined use of a fibrate and orlistat for the treatment of obesity
|
PL1980560T3
(pl)
*
|
2003-03-14 |
2011-11-30 |
Astellas Pharma Inc |
Pochodne C-glikozydowe do leczenia cukrzycy
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
CA2524175C
(en)
*
|
2003-04-28 |
2016-06-14 |
Sankyo Company Limited |
Sugar intake-ability enhancer
|
US9345671B2
(en)
*
|
2003-04-28 |
2016-05-24 |
Daiichi Sankyo Company, Limited |
Adiponectin production enhancer
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
TW200526678A
(en)
*
|
2003-08-01 |
2005-08-16 |
Janssen Pharmaceutica Nv |
Substituted indole-O-glucosides
|
EP1679965A4
(en)
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
|
UA86042C2
(en)
|
2003-08-01 |
2009-03-25 |
Янссен Фармацевтика Н.В. |
Substituted indazole-o-glucosides
|
US7094764B2
(en)
|
2003-08-01 |
2006-08-22 |
Janssen Pharmaceutica N.V. |
Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
|
PL1651658T5
(pl)
|
2003-08-01 |
2020-11-30 |
Mitsubishi Tanabe Pharma Corporation |
Nowe związki o działaniu inhibitującym transporter zależny od sodu
|
RS20060320A
(en)
|
2003-08-01 |
2008-08-07 |
Janssen Pharmaceutica N.V., |
Substituted indazole-o-glucosides
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
US20050054731A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Franco Folli |
Multi-system therapy for diabetes, the metabolic syndrome and obesity
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
GB0322552D0
(en)
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
EP1687410A4
(en)
*
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
ANTISENSE OLIGONUCLEOTIDES OPTIMIZED TO TARGET THE KIDNEY
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ES2524916T3
(es)
|
2003-11-12 |
2014-12-15 |
Sino-Med International Alliance, Inc. |
Compuestos heterocíclicos de ácido borónico
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP1581246B1
(en)
*
|
2003-12-17 |
2013-01-16 |
Amylin Pharmaceuticals, LLC |
Compositions for the treatment and prevention of nephropathy
|
JP2006514649A
(ja)
*
|
2003-12-17 |
2006-05-11 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
腎症の治療および予防のための組成物
|
US7371732B2
(en)
*
|
2003-12-22 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
|
JP5078350B2
(ja)
*
|
2004-03-04 |
2012-11-21 |
キッセイ薬品工業株式会社 |
縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
|
US8058245B2
(en)
|
2004-03-04 |
2011-11-15 |
Kissei Pharmaceutical Co., Ltd. |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
CA2557801C
(en)
*
|
2004-03-16 |
2013-06-25 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
|
WO2005095372A1
(ja)
*
|
2004-03-31 |
2005-10-13 |
Kissei Pharmaceutical Co., Ltd. |
ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
|
CA2560005A1
(en)
*
|
2004-03-31 |
2005-10-13 |
Kissei Pharmaceutical Co., Ltd. |
Phenol derivative, medicinal composition containing the same, and medicinal use thereof
|
TW200602335A
(en)
*
|
2004-03-31 |
2006-01-16 |
Kissei Pharmaceutical |
Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
|
DE602005025755D1
(de)
|
2004-06-04 |
2011-02-17 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
DE102004028241B4
(de)
*
|
2004-06-11 |
2007-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
KR20070048188A
(ko)
*
|
2004-07-08 |
2007-05-08 |
아스텔라스세이야쿠 가부시키가이샤 |
아줄렌 유도체의 제조방법 및 이의 합성 중간체
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
ES2581331T3
(es)
|
2004-07-21 |
2016-09-05 |
Kissei Pharmaceutical Co., Ltd. |
Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
WO2006010557A1
(de)
|
2004-07-27 |
2006-02-02 |
Boehringer Ingelheim International Gmbh |
D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
WO2006018150A1
(de)
*
|
2004-08-11 |
2006-02-23 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
WO2006035796A1
(ja)
*
|
2004-09-29 |
2006-04-06 |
Kissei Pharmaceutical Co., Ltd. |
1-(β-D-グリコピラノシル)-3-置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
|
DE102004048388A1
(de)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
WO2006064033A2
(en)
|
2004-12-16 |
2006-06-22 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200637839A
(en)
|
2005-01-07 |
2006-11-01 |
Taisho Pharmaceutical Co Ltd |
1-thio-d-glucitol derivatives
|
CN101111508B
(zh)
*
|
2005-01-28 |
2011-03-30 |
中外制药株式会社 |
螺缩酮衍生物及其作为糖尿病治疗药物的用途
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
TWI365186B
(en)
|
2005-01-31 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
JP4496174B2
(ja)
*
|
2005-01-31 |
2010-07-07 |
田辺三菱製薬株式会社 |
医薬組成物
|
WO2006086464A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
ATE445608T1
(de)
|
2005-02-23 |
2009-10-15 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
|
CA2599550A1
(en)
*
|
2005-03-11 |
2006-09-21 |
Elixir Pharmaceuticals, Inc. |
Sirt inhibitors that bind to nad
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
ES2338041T3
(es)
*
|
2005-04-15 |
2010-05-03 |
Boehringer Ingelheim International Gmbh |
Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt.
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
US20070015839A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Franco Folli |
Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
|
CA2616294A1
(en)
*
|
2005-07-27 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
CN101268075A
(zh)
*
|
2005-07-28 |
2008-09-17 |
百时美施贵宝公司 |
作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
DE602006017566D1
(de)
*
|
2005-08-30 |
2010-11-25 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
TW200745075A
(en)
|
2005-09-08 |
2007-12-16 |
Boehringer Ingelheim Int |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
AR059489A1
(es)
|
2006-02-15 |
2008-04-09 |
Boehringer Ingelheim Vetmed |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
JP5067644B2
(ja)
*
|
2006-05-19 |
2012-11-07 |
大正製薬株式会社 |
C−フェニルグリシト−ル化合物
|
JP5230613B2
(ja)
*
|
2006-05-23 |
2013-07-10 |
テラコス・インコーポレイテッド |
グルコース輸送体阻害剤およびその使用方法
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
CN101479254B
(zh)
|
2006-06-29 |
2012-05-30 |
大正制药株式会社 |
C-苯基1-硫代山梨醇化合物
|
EP2046753A2
(en)
|
2006-07-06 |
2009-04-15 |
Brystol-Myers Squibb Company |
Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI418556B
(zh)
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
CA2664095A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TWI499414B
(zh)
*
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20100093744A1
(en)
|
2006-10-13 |
2010-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
|
JP2010507629A
(ja)
|
2006-10-27 |
2010-03-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
CA2671699C
(en)
|
2006-12-04 |
2014-07-08 |
Janssen Pharmaceutica N.V. |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
EP2325182A1
(en)
|
2006-12-06 |
2011-05-25 |
Glaxosmithkline LLC |
Bicyclic compounds and use as antidiabetics
|
CN101568537A
(zh)
|
2006-12-21 |
2009-10-28 |
安斯泰来制药有限公司 |
C-糖苷衍生物的制造方法及其合成中间体
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
CA2679310A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
KR101506935B1
(ko)
*
|
2007-04-02 |
2015-03-31 |
테라코스, 인코포레이티드 |
벤질릭 글리코시드 유도체 및 사용 방법
|
WO2008130951A1
(en)
|
2007-04-17 |
2008-10-30 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CN101754972A
(zh)
*
|
2007-05-18 |
2010-06-23 |
百时美施贵宝公司 |
Sglt2抑制剂的晶体结构及其制备方法
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
DK2170930T3
(da)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
|
ATE504591T1
(de)
*
|
2007-07-05 |
2011-04-15 |
Centre Nat Rech Scient |
Neue phosphorhaltige heterocyclische verbindungen,zuckeranaloga und zusammensetzungen mit antikrebswirkung, die diese enthalten
|
CN103254119B
(zh)
*
|
2007-07-10 |
2016-07-06 |
莱西肯医药有限公司 |
钠-葡萄糖协同转运蛋白2的抑制剂及其用法
|
US8026347B2
(en)
*
|
2007-07-26 |
2011-09-27 |
Lexicon Pharmaceuticals, Inc. |
Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
|
EP2173717B9
(en)
*
|
2007-07-27 |
2013-06-26 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
SG188800A1
(en)
|
2007-08-23 |
2013-04-30 |
Theracos Inc |
Benzylbenzene derivatives and methods of use
|
KR101552187B1
(ko)
|
2007-09-10 |
2015-09-10 |
얀센 파마슈티카 엔.브이. |
Sglt 억제제로서 유용한 화합물의 제조 방법
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
WO2009117367A1
(en)
*
|
2008-03-18 |
2009-09-24 |
Bristol-Myers Squibb Company |
Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
|
FR2929615B1
(fr)
|
2008-04-02 |
2010-12-17 |
Tfchem |
Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
|
DE102008017590A1
(de)
*
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
US8791077B2
(en)
|
2008-05-22 |
2014-07-29 |
Astrazeneca Ab |
Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
TWI523652B
(zh)
*
|
2008-07-15 |
2016-03-01 |
泰瑞克公司 |
氘化苄基苯衍生物及使用方法
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
CN102177147A
(zh)
|
2008-08-22 |
2011-09-07 |
泰拉科斯有限公司 |
制备sglt2抑制剂的方法
|
BRPI0918841B8
(pt)
*
|
2008-08-28 |
2021-05-25 |
Pfizer |
derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
PE20120002A1
(es)
|
2009-02-13 |
2012-02-12 |
Boehringer Ingelheim Int |
Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
|
CN102307577A
(zh)
|
2009-02-13 |
2012-01-04 |
贝林格尔.英格海姆国际有限公司 |
包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
|
JP5600328B2
(ja)
|
2009-02-13 |
2014-10-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシルジフェニルメタン誘導体を含む医薬組成物、その医薬剤形、それらの調製方法及び患者の血糖コントロールを改善するためのそれらの使用
|
US8563583B2
(en)
|
2009-03-09 |
2013-10-22 |
Bristol-Myers Squibb Company |
Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
EP2406233B1
(en)
|
2009-03-09 |
2013-11-13 |
Bristol-Myers Squibb Company |
Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
JP2012528170A
(ja)
*
|
2009-05-27 |
2012-11-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
CA2767258C
(en)
|
2009-07-10 |
2016-09-13 |
Janssen Pharmaceutica Nv |
Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
|
JP5736377B2
(ja)
|
2009-09-30 |
2015-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)ベンジル]ベンゼンの結晶形の調製方法
|
WO2011039108A2
(en)
|
2009-09-30 |
2011-04-07 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
EA024368B1
(ru)
|
2009-10-14 |
2016-09-30 |
Янссен Фармацевтика Нв |
Процесс получения соединений для применения в качестве ингибиторов sglt2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
KR20120087950A
(ko)
|
2009-10-20 |
2012-08-07 |
노파르티스 아게 |
글리코시드 유도체 및 그의 용도
|
AP3099A
(en)
|
2009-11-02 |
2015-01-31 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives
|
JP5784623B2
(ja)
|
2009-11-13 |
2015-09-24 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
速放性錠剤製剤
|
WO2011070592A2
(en)
*
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
WO2011130459A1
(en)
|
2010-04-14 |
2011-10-20 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
JP6227406B2
(ja)
|
2010-05-11 |
2017-11-08 |
ヤンセン ファーマシューティカ エヌ.ベー. |
SGLTの阻害剤としての1−(β−D−グルコピラノシル)−2−チエニル−メチルベンゼン誘導体を含有する医薬製剤
|
WO2011153712A1
(en)
*
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
AU2011295837B2
(en)
|
2010-09-03 |
2015-06-18 |
Astrazeneca Uk Limited |
Drug formulations using water soluble antioxidants
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2012106303A1
(en)
|
2011-02-01 |
2012-08-09 |
Bristol-Myers Squibb Company |
Pharmaceutical formulations including an amine compound
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8980829B2
(en)
|
2011-02-18 |
2015-03-17 |
Shanghai Yingli Science And Technology Co., Ltd |
Aryl glycoside compound, preparation method and use thereof
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
CN102675378A
(zh)
*
|
2011-03-09 |
2012-09-19 |
天津药物研究院 |
一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
|
WO2012125622A1
(en)
|
2011-03-14 |
2012-09-20 |
Bristol-Myers Squibb Company |
Substituted adipic acid amides and uses thereof
|
CA2832938C
(en)
|
2011-04-13 |
2019-09-03 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
WO2012140596A1
(en)
|
2011-04-14 |
2012-10-18 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
US8614195B2
(en)
|
2011-04-14 |
2013-12-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
JP5876570B2
(ja)
*
|
2011-06-01 |
2016-03-02 |
グリーン・クロス・コーポレイションGreen Cross Corp. |
Sglt2阻害剤としての新規のジフェニルメタン誘導体
|
MX2013014135A
(es)
|
2011-06-03 |
2014-01-23 |
Boehringer Ingelheim Int |
Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
|
EP2717689A4
(en)
*
|
2011-06-13 |
2014-11-05 |
Panacea Biotec Ltd |
NEW SGLT HEMMER
|
CN102827122B
(zh)
*
|
2011-06-17 |
2015-01-14 |
山东轩竹医药科技有限公司 |
糖苷衍生物
|
CN102875503B
(zh)
*
|
2011-06-25 |
2016-05-25 |
山东轩竹医药科技有限公司 |
C-糖苷衍生物
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8815909B2
(en)
|
2011-07-18 |
2014-08-26 |
Bristol-Myers Squibb Company |
Diaminocyclohexane compounds and uses thereof
|
US8710049B2
(en)
|
2011-07-18 |
2014-04-29 |
Bristol-Myers Squibb Company |
Diaminocyclohexane compounds and uses thereof
|
JP2014530186A
(ja)
|
2011-09-13 |
2014-11-17 |
パナセア バイオテック リミテッド |
新規sglt阻害剤
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
WO2013178064A1
(zh)
*
|
2012-05-29 |
2013-12-05 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2891499A4
(en)
*
|
2012-08-30 |
2016-02-24 |
Taisho Pharmaceutical Co Ltd |
ASSOCIATION OF A SGLT2 INHIBITOR AND AN ANTIHYPERTENSEUR
|
US9586900B2
(en)
|
2012-09-05 |
2017-03-07 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
EP2892897A1
(en)
|
2012-09-05 |
2015-07-15 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
WO2014159151A1
(en)
|
2013-03-14 |
2014-10-02 |
Msd International Gmbh |
Methods for preparing sglt2 inhibitors
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
CN104059042B
(zh)
*
|
2013-03-22 |
2017-02-08 |
正大天晴药业集团股份有限公司 |
C-三芳基葡萄糖苷类sglt-2抑制剂
|
DK2981269T3
(da)
|
2013-04-04 |
2023-10-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af stofskifteforstyrrelser hos hestedyr
|
US20140303098A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AU2014255727B2
(en)
|
2013-04-18 |
2019-07-25 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP2991999B1
(en)
|
2013-04-29 |
2019-05-08 |
Mapi Pharma Limited |
Dapagliflozin lactose co-crystal
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
US10011627B2
(en)
|
2013-09-09 |
2018-07-03 |
Youngene Therapeutics Co., Ltd |
C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof
|
WO2015043511A1
(en)
|
2013-09-27 |
2015-04-02 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
WO2015051484A1
(en)
*
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
SI3862003T1
(sl)
|
2013-12-17 |
2024-02-29 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibitor SGLT-2 za uporabo pri zdravljenju metabolične motnje pri mačjih živalih
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
ES2593050T3
(es)
|
2014-01-03 |
2016-12-05 |
Xuanzhu Pharma Co., Ltd. |
Derivados bencil-4-clorofenil-C-glucósidos ópticamente puros como inhibidores del SGLT (diabetes mellitus)
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
EP3485890B1
(en)
*
|
2014-01-23 |
2023-05-10 |
Boehringer Ingelheim Vetmedica GmbH |
Sglt2 inhibitors for treatment of metabolic disorders in canine animals
|
EP3114115A4
(en)
*
|
2014-03-06 |
2017-08-23 |
MSN Laboratories Private Limited |
Process for the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol and its solvate thereof
|
PT3125882T
(pt)
|
2014-04-01 |
2020-08-17 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
CN105001213B
(zh)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
TW201623321A
(zh)
*
|
2014-05-13 |
2016-07-01 |
韓美藥品股份有限公司 |
雙環衍生物及包含其之藥學組成物
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
CN105085494B
(zh)
*
|
2014-05-22 |
2019-07-02 |
中国医学科学院药物研究所 |
钠糖共转运体2抑制剂、其制法和其药物组合物与用途
|
AU2015320975B2
(en)
|
2014-09-25 |
2020-10-08 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
KR20170049606A
(ko)
|
2014-09-25 |
2017-05-10 |
아스트라제네카 아베 |
간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
US10508128B2
(en)
*
|
2015-02-09 |
2019-12-17 |
Indoco Remedies Limited |
Process for the preparation of SGLT inhibitor compounds
|
CA2979033A1
(en)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
WO2016161995A1
(en)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Solid forms of amorphous dapagliflozin
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
EA201890592A1
(ru)
|
2015-08-27 |
2018-09-28 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
KR102004488B1
(ko)
|
2015-12-11 |
2019-07-26 |
동아에스티 주식회사 |
다파글리플로진의 신규 용매화물 및 이의 제조방법
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
HUE051212T2
(hu)
*
|
2016-01-04 |
2021-03-01 |
Jeil Pharmaceutical Co Ltd |
Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció
|
WO2017141202A1
(en)
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
WO2017221211A1
(en)
*
|
2016-06-24 |
2017-12-28 |
Biocon Limited |
Process for the preparation of dapagliflozin and its solvate thereof
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
KR20190070956A
(ko)
|
2016-10-19 |
2019-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
|
US11020412B2
(en)
|
2017-03-16 |
2021-06-01 |
Inventia Healthcare Limited |
Pharmaceutical composition comprising dapagliflozin
|
US11253508B2
(en)
|
2017-04-03 |
2022-02-22 |
Coherus Biosciences, Inc. |
PPARy agonist for treatment of progressive supranuclear palsy
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
WO2019201752A1
(en)
|
2018-04-17 |
2019-10-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
KR20200022257A
(ko)
*
|
2018-08-22 |
2020-03-03 |
동아에스티 주식회사 |
Sglt-2 억제제인 다파글리플로진 전구체의 제조방법
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN111471031B
(zh)
*
|
2019-01-24 |
2023-05-16 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物及其制备方法和应用
|
CN111471040B
(zh)
*
|
2019-01-24 |
2023-06-02 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物的合成方法及其中间体和应用
|
WO2020151621A1
(zh)
*
|
2019-01-24 |
2020-07-30 |
北京盈科瑞创新药物研究有限公司 |
化合物、其制备方法及医药用途
|
CN111840271B
(zh)
*
|
2019-04-25 |
2024-05-14 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物新用途
|
CN111471032B
(zh)
*
|
2019-01-24 |
2023-08-01 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物的合成方法及其中间体和应用
|
US10973836B2
(en)
|
2019-08-30 |
2021-04-13 |
Astrazeneca Ab |
Methods of treating heart failure with reduced ejection fraction
|
CN114727624A
(zh)
|
2019-11-28 |
2022-07-08 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂在非人哺乳动物的停奶中的用途
|
CA3167531A1
(en)
|
2020-02-17 |
2021-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
EP4114365A1
(en)
|
2020-03-05 |
2023-01-11 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition comprising sglt2 inhibitor
|
IL296035A
(en)
|
2020-03-06 |
2022-10-01 |
Vertex Pharma |
Treatment methods for apol-1 dependent focal segmental tuberous sclerosis
|
US20230201174A1
(en)
|
2020-04-22 |
2023-06-29 |
Bayer Aktiengesellschaft |
Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
|
US20230165856A1
(en)
|
2020-04-29 |
2023-06-01 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
WO2021245253A1
(en)
|
2020-06-05 |
2021-12-09 |
Krka, D.D., Novo Mesto |
Preparation of highly pure amorphous dapagliflozin
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
EP4249479A1
(en)
*
|
2020-11-19 |
2023-09-27 |
Beijing Increase Innovative Drug Co., Ltd. |
Glucoside derivative, and preparation method therefor and application thereof
|
KR20220091233A
(ko)
|
2020-12-23 |
2022-06-30 |
(주)국전약품 |
다파글리플로진 전구약물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
|
EP4315350A1
(en)
|
2021-04-01 |
2024-02-07 |
AstraZeneca UK Limited |
Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
|
AU2022319909A1
(en)
|
2021-07-28 |
2024-02-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
CN117715639A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023179542A1
(en)
|
2022-03-21 |
2023-09-28 |
Gasherbrum Bio , Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
US20230381101A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2024033288A1
(en)
*
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Salicin derivatives as inhibitors of sglt2
|